| 标题： | 先天性肾上腺皮质增生症21羟化酶缺陷症生长发育管理专家共识 |
| title： | Expert consensus on growth and development management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 管理 |
| field： | Administration |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 内分泌科及儿科专科医生 |
| Guide users： | Endocrinologists and Paediatricians |
| 证据分级方法： | 依据牛津循证医学中心（OCEBM）证据分级方法,将纳入的研究证据分为6个证据等级(1a、1b、2a、2b、3、4),并根据证据等级将推荐强度分为A(强)、B(中)、C(弱)3级,以代表共识制订专家组的建议。 |
| Evidence grading method： | According to the evidence ranking schemes from Oxford Centre for Evidence-Based Medicine (OCEBM) , the evidence from the included studies will be divided into 6 levels of evidence (1a, 1b, 2a, 2b, 3, 4), and the strength of the recommendation will be divided into 3 levels according to the level of evidence: A (strong), B (moderate), and C (weak). |
| 制定单位： | 中国医学科学院北京协和医院 |
| Formulating unit： | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences |
| 注册时间： | 2024-03-25 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN460 |
| Registration number： | |
| 指南制订的目的： | 规范21羟化酶缺陷症患者的生长发育治疗和监测，帮助专科医生在21羟化酶缺陷症的儿童生长发育管理中做到准确评估、规范诊治、避免误区。 |
| Purpose of the guideline： | To standardize the treatment and monitoring of growth and development in patients with 21-hydroxylase deficiency, and help specialists to accurately assess, standardize diagnosis and treatment, and avoid misunderstandings in the growth and development management of children with 21-hydroxylase deficiency. |
